Does transcatheter leaflet approximation (TMVr) reduce death and HF hospitalization in heart failure patients with 3+ or 4+ secondary mitral regurgitation?
Heart failure patients with 3+ or 4+ secondary mitral regurgitation, selected using strict echocardiographic criteria
Transcatheter mitral valve repair (TMVr) / transcatheter leaflet approximation
2-year rates of death and HF hospitalizationhard clinical
Strict application of COAPT echocardiographic criteria enables the translation of TMVr benefits (reduced death and HF hospitalization) to clinical practice for patients with secondary mitral regurgitation.
HF patients in the COAPT trial with 3+ or 4+ secondary mitral regurgitation, selected using strict echocardiographic criteria, benefitted from TMVr with reduced 2-year rates of death and HF hospitalization. Strict application of these echocardiographic criteria should enable the COAPT results to be translated to clinical practice. (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation The COAPT Trial COAPT; NCT01626079).
Building similarity graph...
Analyzing shared references across papers
Loading...
Federico M. Asch
Paul Grayburn
Robert J. Siegel
Journal of the American College of Cardiology
The Ohio State University
University of Virginia
Icahn School of Medicine at Mount Sinai
Building similarity graph...
Analyzing shared references across papers
Loading...
Asch et al. (Sat,) studied this question.
www.synapsesocial.com/papers/69d5724275589c71d767e684 — DOI: https://doi.org/10.1016/j.jacc.2019.09.017